SUSAN GRANATO: Open Payments
NPI 1225688427 · BETHESDA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,916 in 80 payments from 32 companies in 2025. Trend: 2023 $0 · 2024 $1,370 · 2025 $3,916
Food & beverage: $2,177Long term medical supply or device loan: $1,097Honoraria: $600Education: $43
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 16 | $1,231 |
| Pharmacosmos Therapeutics Inc. | 3 | $679 |
| BeOne Medicines USA, Inc. | 5 | $243 |
| Incyte Corporation | 6 | $216 |
| Fennec Pharmaceuticals, Inc. | 1 | $172 |
| PharmaEssentia USA Corporation | 4 | $120 |
| GENZYME CORPORATION | 1 | $114 |
| Merck Sharp & Dohme LLC | 5 | $112 |
| Janssen Biotech, Inc. | 5 | $101 |
| Janssen Scientific Affairs, LLC | 1 | $83 |
Products named: KISQALI, COSELA, BRUKINSA, Fyarro, Jakafi, BESREMI, WAYRILZ, KEYTRUDA.
Industry payments across MD — which companies pay providers there.
